Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
about
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old ratsMyostatin from the heart: local and systemic actions in cardiac failure and muscle wastingSkeletal muscle wasting and renewal: a pivotal role of myokine IL-6Cardiac cachexia: hic et nuncCaloric restriction and exercise "mimetics'': Ready for prime time?Nonmuscle Tissues Contribution to Cancer CachexiaSatellite cells in human skeletal muscle plasticityCancer as a Proinflammatory Environment: Metastasis and CachexiaSkeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingMyostatin: expanding horizonsThe quasi-parallel lives of satellite cells and atrophying musclePharmacology of manipulating lean body massMuscle wasting in animal models of severe illnessCellular and molecular mechanisms of muscle atrophyDepletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulationExpression of CCAAT/Enhancer Binding Protein Beta in Muscle Satellite Cells Inhibits Myogenesis in Cancer CachexiaMolecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?Understanding cachexia as a cancer metabolism syndromeMechanisms of metabolic dysfunction in cancer-associated cachexiamRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle massGrowth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophyThe p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteinsDistinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wastingThe methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophyGhrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved.The role of mTOR signaling in the regulation of protein synthesis and muscle mass during immobilization in miceA non-human primate model of radiation-induced cachexia.Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy.Inflammation based regulation of cancer cachexiaActivin A more prominently regulates muscle mass in primates than does GDF8.Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling.The Association of Computed Tomography-Assessed Body Composition with Mortality in Patients with Necrotizing PancreatitisConcurrent evolution of cancer cachexia and heart failure: bilateral effects exist.Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study.Molecular mechanisms of bone metastasis and associated muscle weakness.Panoramic ultrasound: a novel and valid tool for monitoring change in muscle massTherapies for musculoskeletal disease: can we treat two birds with one stone?Muscle abnormalities in osteogenesis imperfecta.Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer.
P2860
Q24564273-A3F0FECF-2B52-4EFB-B844-C474D8325CC1Q24609841-4291C10C-0C36-480A-B84E-42D6ED2F053CQ26743557-BF2CB090-B287-440F-9C7C-04F3575BC857Q26744140-9D41DD5F-3E4A-4ADB-BD0D-20C6D3A9EE05Q26776446-6591B55E-408B-4D84-8BCF-D8CAD8BC529FQ26777562-244FCA4B-7F4A-465C-8A54-987B5DCE65E7Q26777962-20896CB1-7D4E-4B60-8094-88623B46DCE3Q26778324-697BDBF0-9756-4A0B-B2A4-FF59A864D8F3Q26781640-8AF35536-CE4C-4938-979C-5EE62860F6B8Q26797484-C3A3A6C7-60B9-4087-ABB7-73A8D1DE2A8FQ26800207-C70ECBF6-95C2-481A-9C3C-903D385DD9CCQ26824503-C9C14D18-0B22-43A4-83B0-53D64CB2DD26Q27000450-4E26F95E-5AB4-4E42-B2AD-35AD22769B6DQ27012762-ED12CEC6-0ACF-4C87-AF52-A8A59F1A4290Q27312755-D95757E7-187F-4069-873B-61088082DB01Q27334169-E7A22049-1575-4ED3-A3FE-92866F346864Q28068034-885EDBE9-F3B8-46FE-93D0-065820FE23E7Q28069390-6532017F-A285-4A17-8B74-9BABEC1D879DQ28079213-0A482CCE-ECC2-4D98-8271-BE279C17D941Q28239563-60352317-76AC-438C-B8B8-A1FA89855F9FQ28290417-0E72CB27-751D-4A82-8D00-26E849D8CA8AQ28513793-249E19D8-A8AD-478F-A2C7-F2A7B7C21A5FQ28542391-EB0DFED3-DFB5-469E-A07C-BCEC661F8D0AQ28588473-D4377222-3C0A-47FF-A994-4D5C3F35214FQ28592692-02642BAD-DBEE-483D-B753-EC455BD28F65Q30384810-87EDBBF0-8FEC-4DD9-9ADB-8F6C07E3ADE3Q30665419-078477A7-1BEA-4377-8D41-6E307CCB5446Q33390762-6DBEBF44-BBE7-48FC-8D80-954373C96CCAQ33572473-59384E32-93E7-4402-8346-FAF037ED4AA9Q33615916-4FAA78F9-5E3D-4296-9303-4C261051DD9FQ33630598-09A5FEFA-AA81-46AC-B423-F0D2B26C8807Q33700636-9AE0661F-95A7-482C-85FB-34469A662C4CQ33725992-8A922636-67F3-4041-89A7-F24B75F94E5AQ33741091-259751D3-3F9A-457B-826A-6D4AD10D6EA7Q33754369-5F86D635-D776-4196-8EEF-D334BA637E87Q33758508-33B65238-5C69-429B-96EF-9326D3BFCF93Q33813569-E01C8621-B36B-4225-A517-430BD1DD0765Q33851441-D7482F25-6CE9-4970-850E-48F37B75F2BDQ33856898-011FCB3C-CA7F-47F7-88BA-9078B3C3A735Q33912255-77F63EE3-01A3-4788-8E7E-BA7E710FE3C7
P2860
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Reversal of cancer cachexia an ...... m leads to prolonged survival.
@en
Reversal of cancer cachexia an ...... m leads to prolonged survival.
@nl
type
label
Reversal of cancer cachexia an ...... m leads to prolonged survival.
@en
Reversal of cancer cachexia an ...... m leads to prolonged survival.
@nl
prefLabel
Reversal of cancer cachexia an ...... m leads to prolonged survival.
@en
Reversal of cancer cachexia an ...... m leads to prolonged survival.
@nl
P2093
P1433
P1476
Reversal of cancer cachexia an ...... m leads to prolonged survival.
@en
P2093
Alfred L Goldberg
David L Lacey
Jin Lin Wang
Keith S Kwak
Qingsheng Jiao
Robert Rosenfeld
Thomas Boone
P304
P356
10.1016/J.CELL.2010.07.011
P407
P577
2010-08-01T00:00:00Z